Physician profile
Lawrence B Stein
NPI 1306946447
$2,567.90
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $455 · 2021: $632 · 2022: $769 · 2024: $44.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $711.01 | 2019-2022 | |
| Janssen Biotech, INC. | $406.60 | 2019-2022 | |
| Abbvie INC. | $372.18 | 2019-2022 | |
| Pfizer INC. | $266.40 | 2019-2022 | |
| Gilead Sciences, INC. | $155.94 | 2019-2022 | |
| Celgene Corporation | $138.49 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.28 | 2019-2022 | |
| Braintree Laboratories, INC. | $67.37 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $59.54 | 2021 | |
| Ironwood Pharmaceuticals, INC | $52.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.82 | 2019-2022 | |
| Redhill Biopharma INC. | $41.52 | 2021 | |
| Medtronic, INC. | $38.11 | 2021-2024 | Endoflip |
| Becton, Dickinson and Company | $30.65 | 2022 | |
| Intercept Pharmaceuticals, INC. | $29.03 | 2020-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $23.88 | 2024 | Resmetirom |
| Ambu INC. | $23.61 | 2020 | |
| Qol Medical, LLC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.